These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17265509)

  • 1. Tumor necrosis factor alpha blockers and metastases: comment on the article by Setoguchi et al.
    McGrath H
    Arthritis Rheum; 2007 Feb; 56(2):695-6; author reply 696. PubMed ID: 17265509
    [No Abstract]   [Full Text] [Related]  

  • 2. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
    Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
    Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
    [No Abstract]   [Full Text] [Related]  

  • 3. Rheumatoid arthritis: anticytokine therapies on the horizon.
    Koopman WJ; Moreland LW
    Ann Intern Med; 1998 Feb; 128(3):231-3. PubMed ID: 9454532
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Schiff MH
    Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):101-4. PubMed ID: 10355058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al.
    van der Laken CJ; Lems WF; van Soesbergen RM; van der Sande JJ; Dijkmans BA
    Arthritis Rheum; 2003 Jan; 48(1):269-70. PubMed ID: 12528130
    [No Abstract]   [Full Text] [Related]  

  • 7. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 8. [When are "biologics" indicated?].
    MMW Fortschr Med; 2006 Apr; 148(17):10. PubMed ID: 16711479
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of the biologic response modifiers.
    Markenson J
    Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):15-9. PubMed ID: 17491583
    [No Abstract]   [Full Text] [Related]  

  • 10. [Redefining treatment of rheumatic arthritis with anti-cytokines].
    Gabay C; So A
    Rev Med Suisse; 2007 Mar; 3(103):715-7. PubMed ID: 17458148
    [No Abstract]   [Full Text] [Related]  

  • 11. An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti-tumor necrosis factor therapy: comment on the article by Dixon et al.
    Holman AJ
    Arthritis Rheum; 2008 Jun; 58(6):1886; author reply 1886. PubMed ID: 18512805
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in targeted therapies V: Proceedings of the 5th International Symposium. St Martin, French West Indies. 11-14 April 2003.
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2():ii1-96. PubMed ID: 14532137
    [No Abstract]   [Full Text] [Related]  

  • 13. How antirheumatic drugs protect joints from damage in rheumatoid arthritis.
    Schett G; Stach C; Zwerina J; Voll R; Manger B
    Arthritis Rheum; 2008 Oct; 58(10):2936-48. PubMed ID: 18821703
    [No Abstract]   [Full Text] [Related]  

  • 14. Concerns regarding the readministration of tumor necrosis factor alpha antagonists following tuberculosis flare: comment on the concise communication by Aslanidis et al.
    Chogle AR; Mishra H; Deo SS
    Arthritis Rheum; 2008 Sep; 58(9):2923-4. PubMed ID: 18759280
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bisphosphonates on interleukin 1, tumor necrosis factor alpha, and beta 2 microglobulin in rheumatoid arthritis.
    Cantatore FP; Introsso AM; Carrozzo M
    J Rheumatol; 1996 Jun; 23(6):1117-8. PubMed ID: 8782156
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapeutic approaches of rheumatic disorders.
    Houssiau FA; Lauwerys BR
    Acta Clin Belg; 1998 Jun; 53(3):155-61. PubMed ID: 9701849
    [No Abstract]   [Full Text] [Related]  

  • 19. New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs.
    Fye KH
    Postgrad Med; 1999 Oct; 106(4):82-5, 88-90, 92. PubMed ID: 10533510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter by Lensen et al regarding article, "anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis".
    Lensen KJ; van Sijl AM; Smulders YM
    Circulation; 2013 Jul; 128(1):e10. PubMed ID: 23817487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.